Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics?

Author:
  • Carl A K Borrebaeck
  • Ann-Christin Malmborg
  • Mats Ohlin
Publishing year: 1993
Language: English
Pages: 477-479
Publication/Series: Immunology Today1980-01-01+01:002001-01-01+01:00
Volume: 14
Issue: 10
Document type: Journal article
Publisher: Elsevier

Abstract english

Monoclonal antibodies have many potential therapeutic benefits. However, when applied to humans, mouse monoclonal antibodies have several disadvantages. Here Carl Borrebaeck and colleagues describe a strategy to overcome the anti-Gal activity, thought to be one of the reasons why mouse mAbs have a limited half-life.

Other

Published
  • ISSN: 0167-5699
Carl Borrebaeck
E-mail: carl [dot] borrebaeck [at] immun [dot] lth [dot] se

Professor

Department of Immunotechnology

313k1

90

Director

Create Health

+46 46 222 96 13

313k1

90